A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.
A Double Blind, Randomized, Placebo Controlled, Parallel Group Dose-range Exploration Study of Sativex® in Relieving Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy.
Sponsor: GW Pharmaceuticals Ltd
A PHASE2 clinical study on Cancer and Pain, this trial is completed. The trial is conducted by GW Pharmaceuticals Ltd and has accumulated 10 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Mar 2022 — Dec 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GW Pharmaceuticals Ltd
- Quintiles, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany, Almería, Spain, Andhra Pradesh, India, Austin, United States, Baia Mare, Maramures, Romania, Bangalore, India, Barcelona, Spain, Basingstoke, United Kingdom, Benešov, Czechia, Berkeley Heights, United States and 91 more location s